News

Block Admission Return
Block Admission Return
April 4, 2018

Block Admission Return

License Agreement Extension with Thermo Fisher Scientific
License Agreement Extension with Thermo Fisher Scientific
April 3, 2018

Electrophoretics Ltd, a wholly owned subsidiary of Proteome Sciences plc, is pleased to announce that it has signed an amendment to the exclusive License and Distribution Agreement with Pierce Biotechnology Inc., a part of Thermo Fisher Scientific Inc., extending the current license to include intellectual property relating to a new class of higher-plex TMT® reagents currently in development. 

Notice of Results
Notice of Results
March 29, 2018

The Directors look forward to updating shareholders on the Company’s performance, and on the outlook for 2018, at the time we announce our 2017 full year results which are scheduled for release on 24 April 2018.

Annual General Meeting

The Annual General Meeting will take place in London during the last week of May 2018 and further details will be provided in due course.

 

Director/PDMR Shareholding
Director/PDMR Shareholding
March 22, 2018

Director/PDMR Shareholding

The Company announces that on 21 March 2018 Roger McDowell, a Non-Executive Director of the Company, sold 500,000 ordinary shares of 1 pence each ("Ordinary Shares") at a price of 3 pence per Ordinary Share and bought, into his SIPP, 500,000 Ordinary Shares at a price of 3.006 pence per Ordinary Share (the "Transfer").

Trading Update 12th February 2018
Trading Update 12th February 2018
February 12, 2018

The Company today provides a trading update for the 12 months ending 31 December 2017.

Commenting on this update Jeremy Haigh, Chief Executive Officer of Proteome Sciences, said  "While progress was slower than we would have wished during 2017, particularly on the services side of the business where early adoption has been challenging, this is not surprising given the scale of change undertaken by the company in the first half of the year. However, with the benefits of a leaner organisation, a new model for commercial engagement now fully deployed in both our principal operating territories and the reassurance of robust and increasing demand for our TMT® reagents, we have the platform necessary to realise the full value of our available proteomic technologies.  Following fundamental changes to our services business we are encouraged by stronger performance in the fourth quarter of 2017 and the order book moving into 2018.  It is now possible to consider the range of options available to a company with our ambition; I look forward to doing this and to providing further updates throughout the course of the year."

Holdings in Company
Holdings in Company
November 10, 2017
Holdings in Company  - TR1 notification was received from Spreadex Limited on the 10th November 2017.
Director/PDMR Shareholding
Director/PDMR Shareholding
November 8, 2017

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 06 November 2017, it purchased 20,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.17p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 55,217,431 equivalent to 18.71% of Proteome Sciences' total issued share capital.

 

Director/PDMR Shareholding
Director/PDMR Shareholding
October 27, 2017

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 24 October 2017 and 25 October 2017, it purchased 75,000 and 109,460 ordinary shares of 1p each, respectively, in the capital of the Company ("Ordinary Shares") at an average price of 3.18p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 55,197,431 equivalent to 18.69% of Proteome Sciences' total issued share capital.

 

Director/PDMR Shareholding
Director/PDMR Shareholding
October 23, 2017

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 18 and 19 October 2017 it purchased 256,520 and 193,100 ordinary shares of 1p each, respectively, in the capital of the Company ("Ordinary Shares") at an average price of 3.075p per Ordinary Share (the “Purchase”) and on 20 October it purchased 119,636 ordinary shares of 1p each at a price of 3.15p per Ordinary Share. Following the Purchase, Vulpes has a total direct and indirect interest in 55,012,971 equivalent to 18.64% of Proteome Sciences' total issued share capital.

GCLP Accreditation and Trading Update
GCLP Accreditation and Trading Update
October 18, 2017

The Company is pleased to announce the receipt of Good Clinical Laboratory Practice (GCLP) accreditation which will now enable it to compete effectively for clinical stage contracts commanding routinely larger budgets; the benefits of this should start being reflected early in 2018.

Commenting on this update Jeremy Haigh, Chief Executive Officer of Proteome Sciences, said “We are working hard to establish Proteome Sciences as a successful services business and are beginning to see the benefits of the comprehensive restructuring and refocusing which was initiated earlier in the year. While we would have liked greater progress to date, revenues continue to grow well and we are witnessing a material increase in enquiry and engagement levels during the second half, particularly from the US.  We remain confident that this can be reliably converted into service-based revenues in the near to medium term and are pleased that increasing demand for our TMT® reagents continues to underpin our overall revenue growth and prospects.”